UnknownPhase 2NCT04718584
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
Studying Adenocarcinoma of the penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
- Principal Investigator
- Dingwei YeFudan University
- Intervention
- Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)(drug)
- Enrollment
- 127 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2020 – 2023
Study locations (1)
- Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai, Shanghai Municipality, China
Collaborators
Fudan University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04718584 on ClinicalTrials.govOther trials for Adenocarcinoma of the penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05639972E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersChristian Hinrichs
- RECRUITINGPHASE1NCT07118176Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersJonsson Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06683846Ivonescimab in the Treatment of Multiple Advanced TumorsFudan University
- RECRUITINGPHASE2NCT05686226E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersChristian Hinrichs
- RECRUITINGPHASE2NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT03333616Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE1NCT02496208Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsNational Cancer Institute (NCI)